Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

Prior treatment

• Use of amiodarone 12 months prior to enrollment
• History of AF ablation within 30 days prior to enrollment
• Women of child-bearing potential (those who have had a menstrual period in the previous 12 months) who:
  • are pregnant or breast-feeding or plan to become pregnant during study or
  • who are not surgically sterile and are not practicing two acceptable methods of birth control, or do not plan to continue practicing two acceptable methods of birth control throughout the study (highly effective methods are listed under section 6.0 Pregnancy)
• Not able to discontinue medications known to have significant interactions with chloroquine

Other illness

• AF felt to be secondary to an obvious reversible cause such as, but not limited to, acute myocardial infarction, pulmonary embolism, recent surgery, pericarditis, alcohol intoxication, hypoxemia, or thyrotoxicosis
• Structural heart disease including patients with artificial heart valves or valvular AF
• Obstructive coronary artery disease or history of any myocardial infarction
• Known allergy or hypersensitivity to Chloroquine
• History of alcohol abuse and/or drug abuse per PI discretion
• History of epilepsy
• Serious or active medical or psychiatric condition which, in the opinion of the investigator, may interfere with treatment, assessment, or compliance with the protocol

Lab values

• Ejection fraction \< 50% within 1 year of consent
• Prolonged QTc of \>460 msec on baseline ECG
• Renal impairment (eGFR \< 30 mL/min/1.73 m2 or Serum Creatinine \> 1.25 mg/dL) for subjects over the age of 65
• Hepatic disease (ALT/AST 2X the upper normal limit)

Age

• Age \< 18 years

Other

• Severe or moderate to severe aortic stenosis, mitral stenosis, aortic regurgitation, or mitral regurgitation per PI discretion
• Contraindications to quinolines
• Pre-existing auditory damage
• Current participation in another clinical study

• Age 18 years and older
• History of symptomatic persistent AF Persistent AF - defined as continuous AF that is sustained more than 7 days but less than 12 months. Episodes of AF of ≥ 48 hours duration in which a decision is made to terminate with electrical or pharmacological cardioversion prior to 7 days will also be classified as persistent AF
• AF must be documented at least once either by ECG, event monitoring, loop recorder, telemetry, trans-telephonic monitoring, pacemaker or cardiac defibrillator readouts within 24 months prior to enrollment
• Currently on anticoagulation therapy as indicated per local guidelines, which is considered optimal for stroke prevention in the opinion of the investigator
• Implanted dual chamber pacemaker/ICD capable of monitoring atrial arrhythmias or willingness to wear a 2 weeks event monitor if patient does not have a device capable of monitoring atrial arrhythmias
• Signed informed consent